Ebselen, a new candidate therapeutic against SARS-CoV-2.

Haritha, C V; Sharun, Khan; Jose, Bosco

Haritha, C V; Sharun, Khan; Jose, Bosco.

Haritha CV; Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India.
Sharun K; Division of Surgery, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India. Electronic address: sharunkhansk@gmail.com.
Jose B; Division of Physiology & Climatology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India.

Int J Surg ; 84: 53-56, 2020 12.

Article in English | MEDLINE | ID: covidwho-1385734

Subject(s)

COVID-19; SARS-CoV-2; Azoles; Humans; Isoindoles; Laboratories; Organoselenium Compounds; Polymerase Chain Reaction; Tomography, X-Ray Computed

Keywords

COVID-19; Clinical trials; Ebselen; Main protease; Repurposed drug; SARS-CoV-2; Therapeutics

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: English Journal: Int J Surg Year: 2020 Document Type: Article Affiliation country: J.IJSU.2020.10.018

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google